Replimune Group, Inc. Faces Class Action Lawsuit for Securities Violations

Class Action Lawsuit Filed Against Replimune Group, Inc.

On September 22, 2025, the DJS Law Group announced a significant class action lawsuit against Replimune Group, Inc., known by its ticker symbol REPL on NASDAQ. This lawsuit claims that the company violated sections of the Securities Exchange Act of 1934, specifically §§10(b) and 20(a), as well as Rule 10b-5 instituted by the U.S. Securities and Exchange Commission (SEC).

The allegations state that Replimune made false and misleading statements regarding its clinical trial, known as the IGNYTE trial, for the investigational treatment RP1 (vusolimogene oderparepvec). This information misled investors about the trial’s true potential and violated key securities regulations. As a result, many investors feel they were misinformed about their investment prospects during the class period spanning from November 22, 2024, to July 21, 2025.

Details of the Class Period

During this class period, numerous shareholders purchased stock in Replimune, unaware of the serious issues concerning the clinical trial. The lawsuit points to the company’s knowledge of problems that would likely lead the FDA to assert that the trial lacked proper controls, thus fundamentally undermining the integrity of their public disclosures. The legal action claims that these misleading statements had a material impact on the stock price, leading to financial losses for investors.

Encouragement for Affected Shareholders

Investors who purchased shares during the specified timeframe are encouraged to reach out to the DJS Law Group to discuss appointments as lead plaintiffs. Importantly, the firm notes that one does not need to be a lead plaintiff to participate in recovering any potential losses linked to the lawsuit.

As part of the next steps, registered shareholders will be enrolled in a monitoring program that keeps them updated about the case's progress. Joining this case involves no fees or obligations, making it an accessible opportunity for affected investors.

Why Choose DJS Law Group?

DJS Law Group emphasizes its commitment to enhancing investor returns through a combination of effective counsel and vigorous representation. They specialize in securities litigation and corporate governance matters, positioning them well to handle high-stakes legal proceedings. The firm represents a variety of significant clients, including some of the world’s largest hedge funds and alternative investment managers, indicating a level of expertise that is crucial for navigating complex legal situations such as shareholder class actions.

As the lawsuit proceeds, affected investors are encouraged to consider their rights and the potential for recovery. The DJS Law Group is dedicated to ensuring that investors have the necessary support in navigating this process.

In summary, Replimune Group, Inc. finds itself in a challenging legal predicament that could have extensive implications for its investors. Those who believe they have suffered financial loss due to the company's alleged misconduct should act promptly to discuss their options with legal experts specialized in securities law.

For more information, investors can contact:
David J. Schwartz
DJS Law Group
274 White Plains Road, Suite 1
Eastchester, NY 10709
Phone: 914-206-9742
Email: [email protected]